SCHEMBL5068360

SCHEMBL5068360

CCOC(=O)CCc1ccc(-c2cccnc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.56
CYP4A11 Q02928 1/20 0.56
MKNK1 Q9BUB5 3/20 0.51
MKNK2 Q9HBH9 3/20 0.51
SYK P43405 3/20 0.50
PSMB5 P28074 1/20 0.50
CYP4Z1 Q86W10 1/20 0.49
LMNA P02545 1/20 0.48
POLB P06746 1/20 0.48
MMP2 P08253 1/20 0.48
MMP13 P45452 1/20 0.48
MMP14 P50281 1/20 0.48
HRH3 Q9Y5N1 1/20 0.48
CYP2A6 P11509 1/20 0.48
HDAC1 Q13547 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12646562 0.86 HDAC1 (0.60) MKNK1MKNK2PSMB5HRH3CYP2A6
SCHEMBL29001632 0.86 MKNK1 (0.54) MKNK1MKNK2SYKLMNAPOLB
SCHEMBL3957320 0.84 CYP4F2 (0.55) CYP4F2CYP4A11MEN1KMT2A
SCHEMBL2772418 0.84 CYP4F2 (0.68) CYP4F2CYP4A11CYP4Z1HRH3
SCHEMBL11062768 0.84 TBXAS1 (0.66) CYP4F2CYP4A11CYP4Z1LMNA
Hydrochloric Acid SCHEMBL27552763 0.83 CYP4F2 (0.54) CYP4F2CYP4A11MEN1KMT2A
Hydrochloric Acid SCHEMBL18230734 0.83 CYP4F2 (0.54) CYP4F2CYP4A11MEN1KMT2A
SCHEMBL10663180 0.82 CYP4F2 (0.54) CYP4F2CYP4A11CYP4Z1MMP13
SCHEMBL2386306 0.80 FFAR1 (0.69) MKNK1MKNK2CYP2A6HDAC1
SCHEMBL3384358 0.80 HDAC1 (0.55) MKNK1MKNK2LMNAPOLBMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410984-B2 Compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-08-12 US disclosed
US-20050288337-A1 Novel compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2005-12-29 US disclosed
CN-1688548-A Process for preparing quinolin antibiotic intermediates TANABE SEIYAKU CO (JP) 2005-10-26 CN disclosed
EP-1539696-A2 PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 2005-06-15 EP disclosed
WO-2004014859-A2 PROCESS FOR PREPARING QUINOLIN ANTIBIOTIC INTERMEDIATES TANABE SEIYAKU CO., LTD. (JP) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288337-A1 Novel compounds ITGB4, ITGA4, ITGB5 CYP4F2 1416/4885CYP4A11 2202/4885MKNK1 1236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.